Welcome to our dedicated page for Alvotech news (Ticker: ALVO), a resource for investors and traders seeking the latest updates and insights on Alvotech stock.
Alvotech develops and manufactures biosimilar medicines for global markets. Company news centers on its approved and marketed biosimilars to Humira, Stelara, Simponi, Eylea and Prolia/Xgeva, along with disclosed candidates for autoimmune disorders, eye disorders, osteoporosis, respiratory disease and cancer.
Recurring updates cover financial results, annual reporting, FDA interactions tied to the Reykjavik manufacturing facility, biosimilar study results such as AVT80, supply and commercialization partnerships, intellectual-property settlements, executive changes and manufacturing-platform developments. Alvotech also reports on global commercial reach through partners across the United States, Europe, Japan, China and other international markets.
Alvotech (NASDAQ: ALVO) priced an underwritten public offering of 22,666,667 ordinary shares at $3.75 per share, targeting gross proceeds of about $85 million, or $98 million if underwriters exercise a 3.4 million-share option.
A concurrent private placement of 17,826,666 shares at $3.75 is expected to raise about $67 million, bringing total gross proceeds to roughly $152–165 million. According to Alvotech, net proceeds will support biosimilar development, working capital, general corporate purposes and possible debt repayment.
Alvotech (NASDAQ: ALVO) has launched an underwritten public offering of ordinary shares and a concurrent private placement, targeting approximately $125 million in gross proceeds. A 30-day underwriter option for up to 15% additional shares is expected. Proceeds will fund biosimilar development, working capital and general corporate purposes.
Alvotech (ALVO) published a filing with the Luxembourg financial regulator CSSF detailing a manager transaction.
The filing reports the allocation of shares to a board director, granted in accordance with his agreed remuneration package, and is disclosed as a transaction of managers and closely associated persons.
Alvotech (NASDAQ: ALVO) announced FDA acceptance for review of its Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio (vedolizumab) IV. Under its partnership with Teva, Alvotech handles development and manufacturing, while Teva leads commercialization.
The BLA is backed by analytical, pharmacokinetic and immunogenicity data to support biosimilarity. AVT16 targets adults with moderately to severely active ulcerative colitis and Crohn’s disease. A pivotal pharmacokinetic study of AVT80, another Entyvio biosimilar candidate, met all primary endpoints and supports clinical similarity for both AVT16 and AVT80.
Alvotech (NASDAQ: ALVO) resubmitted U.S. FDA Biologics License Applications for AVT05, a proposed biosimilar to Simponi and Simponi Aria, and AVT06, a proposed biosimilar to Eylea 2 mg.
The resubmissions follow responses to an FDA Post-Application Action Letter and cGMP inspection observations at Alvotech’s Reykjavik facility. The company expects a six-month FDA review.
Alvotech (NASDAQ:ALVO) held its 2026 Annual and Extraordinary General Meeting on June 3, 2026, in Luxembourg. All draft resolutions on the agenda were approved. Notarized minutes and detailed voting results will be made available on the company’s dedicated 2026 AGM web portal.
Alvotech (NASDAQ: ALVO) announced that Founder and Executive Chairman Robert Wessman and Chief Strategy Officer Dr. Balaji V. Prasad will speak at three investor events in June 2026.
They will join fireside chats at Jefferies Global Healthcare, Goldman Sachs Global Healthcare, and UBS Virtual Generics and Biosimilars Day, all with live and archived webcasts.
Alvotech (Nasdaq: ALVO) and Islandsbanki renewed and amended their market making agreement for ALVO shares on Nasdaq Iceland. Islandsbanki will place bid and ask quotes with an aggregate market value of at least ISK 8 million and a maximum spread of 2.5%. The daily net trading volume is capped at ISK 16 million. The amended, open-ended agreement was executed on May 29, 2026, and can be terminated by either party with 7 days’ notice.
Alvotech (NASDAQ: ALVO) reported completion of a routine FDA cGMP surveillance inspection at its Reykjavik, Iceland manufacturing facility, ending May 8, 2026, with issuance of a Form 483.
The company believes observations are addressable, remains on track to resubmit the relevant BLAs in Q2 2026, and continues to expect FDA approvals during 2026.
Alvotech (NASDAQ: ALVO) reported Q1 2026 revenue of $105.9m versus $132.8m year-ago and adjusted EBITDA $24.4m with gross margin 57%. Management said production slowdowns for facility improvements reduced near-term volumes. Post-period, Alvotech filed EMA applications for AVT16 and AVT80, started a pivotal AVT29 study for high-dose Eylea HD, and signed a U.S. manufacturing agreement with FUJIFILM Biotechnologies. 2026 guidance: revenues $650–700m and adjusted EBITDA $180–220m.